

## CROSS-REFERENCE TO RELATED APPLICATIONS

A2 This application is a continuation of U.S. Patent Application No. 08/871,488, filed on June 9, 1997, which issued as U.S. Patent No. 6,358,710; which application is a continuation-in-part of U.S. Patent Application No. 08/660,362, filed on June 7, 1996 and abandoned; all of which applications are incorporated herewith in their entirety.

Please amend paragraph beginning at line 6 of page 48 to read as follows:

A3 Essentially, the cDNA sequence encoding the variable regions of NR-LU-13 antibody (hybridoma producing the antibody was deposited with American Type Culture Collection (10801 University Blvd., Manassas, VA 20110) as ATCC Accession No. SD3273, converted to ATCC Accession No. CRL-12360 were cloned and sequenced by known methods. The cDNA sequences of the cloned light and heavy sequence of NR-LU-13 are contained in Figure 2. Using these sequences, the amino acid sequence of the Fv region of NR-LU-13 which includes the entire variable light and variable heavy regions was elucidated.

Please amend paragraph beginning at line 12 of page 56 to read as follows:

A4 The highest producing clone was selected (C2-451C4-100nM HP-2 $\mu$ M HP-161E12-50 $\mu$ M) and subjected to 2 rounds of limiting dilution cloning in 96-well plates in IMDM containing 10% dFBS and 50  $\mu$ M Methotrexate before cell banking. The final clone was designated C2-451C4-100nM HP-2 $\mu$ M HP-161E12-50 $\mu$ M-12G4-3E7 (hybridoma producing the antibody was deposited with American Type Culture Collection (10801 University Blvd., Manassas, VA 20110) as ATCC Accession No. SD3273, converted to ATCC Accession No. CRL-12360.